ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07875
0,00%
Bitcoin
60.731,42
-0,11%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. BiondVax Pharmaceuticals Ltd (BVXV)

  7. BiondVax Pharmaceuticals Ltd (BVXV) News

BVXV

BiondVax Pharmaceuticals (BVXV)

BiondVax Pharmaceuticals Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BVXV
DatumZeitQuelleÜberschriftSymbolFirma
30/04/202422h06Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
16/04/202423h27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
10/04/202413h00PR Newswire (US)Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202421h17Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202413h00PR Newswire (US)Scinai leadership to attend BIO-Europe Spring 2024NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
13/02/202413h00PR Newswire (US)Scinai Welcomes Liat Halpert as Head of Business Development and SalesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
04/01/202422h01PR Newswire (US)Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
20/11/202313h30PR Newswire (US)Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity RuleNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/09/202323h27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/09/202318h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/09/202317h44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/09/202312h00GlobeNewswire Inc.BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological TherapeuticsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
28/08/202322h01Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
28/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
24/08/202322h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/08/202312h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202322h16Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202316h07Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
14/08/202312h08Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/08/202315h44Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/08/202315h00GlobeNewswire Inc.BiondVax Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
01/08/202322h01GlobeNewswire Inc.Nasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
01/08/202322h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/07/202321h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/07/202314h17GlobeNewswire Inc.IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
05/07/202315h17Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/07/202322h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/07/202322h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/06/202322h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
05/06/202313h00GlobeNewswire Inc.BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:BVXV

Kürzlich von Ihnen besucht

NYSE
MCD
McDonalds
CCOM
SILVER
SILVER
TG
BAYN
Bayer
AMEX
XLF
Financial Select Sector
TG
432
Arbor Metals
COIN
BTCUSD
Bitcoin
DBI
TDXP
Tec DAX
NYSE
DIS
Walt Disney
TG
RHM
Rheinmetall
NYSE
MRK
Merck
NYSE
KO
Coca Cola
TG
DBK
Deutsche Bank
AMEX
XLE
Energy Select Sector SPDR
TG
TUI1
Tui
AMEX
SPY
SPDR S&P 500
USOTC
DTEGY
Deutsche Telekom (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten